Researchers continue to be the targets of legal action from pharmaceutical, medical device, and nutraceutical companies when their studies frame products in an unfavorable light.
A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.
Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.
Patients who develop pulmonary edema after starting prostacyclin for pulmonary arterial hypertension have a greater risk for mortality.
Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.
Researchers assessed the efficacy of a once-daily treatment option for controlled asthma.
Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.
A recent study examined whether nebulized glycopyrrolate is safe to use in patients with severe COPD and comorbid cardiovascular risk factors.
The safety of concurrently administering nebulized glycopyrrolate with long-acting beta agonists was examined in 3 studies.